ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1

por Moiseeva, Tatiana, Hood, Brian, Schamus, Sandy, O’Connor, Mark J., Conrads, Thomas P., Bakkenist, Christopher J.
Publicado 2017

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

por Vendetti, Frank P., Lau, Alan, Schamus, Sandra, Conrads, Thomas P., O'Connor, Mark J., Bakkenist, Christopher J.
Publicado 2015

Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models

por Tran Chau, Vanessa, Liu, Winchygn, Gerbé de Thoré, Marine, Meziani, Lydia, Mondini, Michele, O’Connor, Mark J., Deutsch, Eric, Clémenson, Céline
Publicado 2020

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells

por Gomez, Miriam K., Illuzzi, Giuditta, Colomer, Carlota, Churchman, Michael, Hollis, Robert L., O’Connor, Mark J., Gourley, Charlie, Leo, Elisabetta, Melton, David W.
Publicado 2020

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition

por Jamal, Kunzah, Galbiati, Alessandro, Armenia, Joshua, Illuzzi, Giuditta, Hall, James, Bentouati, Sabrina, Barrell, Daniel, Ahdesmäki, Miika, O'Connor, Mark J., Leo, Elisabetta, Forment, Josep V.
Publicado 2022

Correction to Oplustilova L, et al. Cell Cycle Volume 11, Issue 20; pp. 3837–50

por Oplustilova, Lenka, Wolanin, Kamila, Mistrik, Martin, Korinkova, Gabriela, Simkova, Dana, Bouchal, Jan, Lenobel, Rene, Bartkova, Jirina, Lau, Alan, O’Connor, Mark J., Lukas, Jiri, Bartek, Jiri
Publicado 2013

Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress

por Lloyd, Rebecca L, Urban, Vaclav, Muñoz-Martínez, Francisco, Ayestaran, Iñigo, Thomas, John C, de Renty, Christelle, O’Connor, Mark J, Forment, Josep V, Galanty, Yaron, Jackson, Stephen P
Publicado 2021

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

por Borst, Gerben R., Kumareswaran, Ramya, Yücel, Hatice, Telli, Seyda, Do, Trevor, McKee, Trevor, Zafarana, Gaetano, Jonkers, Jos, Verheij, Marcel, O’Connor, Mark J., Rottenberg, Sven, Bristow, Robert G.
Publicado 2017

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

por Borst, Gerben R., Kumareswaran, Ramya, Yücel, Hatice, Telli, Seyda, Do, Trevor, McKee, Trevor, Zafarana, Gaetano, Jonkers, Jos, Verheij, Marcel, O’Connor, Mark J., Rottenberg, Sven, Bristow, Robert G.
Publicado 2020

Investigation of Radiosensitivity Gene Signatures in Cancer Cell Lines

por Hall, John S., Iype, Rohan, Senra, Joana, Taylor, Janet, Armenoult, Lucile, Oguejiofor, Kenneth, Li, Yaoyong, Stratford, Ian, Stern, Peter L., O’Connor, Mark J., Miller, Crispin J., West, Catharine M. L.
Publicado 2014

Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model

por Jiang, Yanyan, Martin, Jennifer, Alkadhimi, Maryam, Shigemori, Kay, Kinchesh, Paul, Gilchrist, Stuart, Kersemans, Veerle, Smart, Sean, Thompson, James M., Hill, Mark A., O’Connor, Mark J., Davies, Barry R., Ryan, Anderson J.
Publicado 2021

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

por Wilson, Zena, Odedra, Rajesh, Wallez, Yann, Wijnhoven, Paul W.G., Hughes, Adina M., Gerrard, Joe, Jones, Gemma N., Bargh-Dawson, Hannah, Brown, Elaine, Young, Lucy A., O'Connor, Mark J., Lau, Alan
Publicado 2022

Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation

por Vendetti, Frank P., Leibowitz, Brian J., Barnes, Jennifer, Schamus, Sandy, Kiesel, Brian F., Abberbock, Shira, Conrads, Thomas, Clump, David Andy, Cadogan, Elaine, O’Connor, Mark J., Yu, Jian, Beumer, Jan H., Bakkenist, Christopher J.
Publicado 2017

ATM protein is deficient in over 40% of lung adenocarcinomas

por Villaruz, Liza C., Jones, Helen, Dacic, Sanja, Abberbock, Shira, Kurland, Brenda F., Stabile, Laura P., Siegfried, Jill M., Conrads, Thomas P., Smith, Neil R., O'Connor, Mark J., Pierce, Andrew J., Bakkenist, Christopher J.
Publicado 2016

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

por Gill, Sonja J., Wijnhoven, Paul W.G., Fok, Jacqueline H.L., Lloyd, Rebecca L., Cairns, Jonathan, Armenia, Joshua, Nikkilä, Jenni, Lau, Alan, Bakkenist, Christopher J., Galbraith, Susan M., Vens, Conchita, O'Connor, Mark J.
Publicado 2021

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative...

por Min, Ahrum, Im, Seock-Ah, Kim, Debora Keunyoung, Song, Sang-Hyun, Kim, Hee-Jun, Lee, Kyung-Hun, Kim, Tae-Yong, Han, Sae-Won, Oh, Do-Youn, Kim, Tae-You, O’Connor, Mark J, Bang, Yung-Jue
Publicado 2015

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours

por Ordonez, Liliana D., Hay, Trevor, McEwen, Robert, Polanska, Urszula M., Hughes, Adina, Delpuech, Oona, Cadogan, Elaine, Powell, Steve, Dry, Jonathan, Tornillo, Giusy, Silcock, Lucy, Leo, Elisabetta, O’Connor, Mark J., Clarke, Alan R., Smalley, Matthew J.
Publicado 2019

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

por Winkler, Claudia, Armenia, Joshua, Jones, Gemma N., Tobalina, Luis, Sale, Matthew J., Petreus, Tudor, Baird, Tarrion, Serra, Violeta, Wang, Anderson T., Lau, Alan, Garnett, Mathew J., Jaaks, Patricia, Coker, Elizabeth A., Pierce, Andrew J., O’Connor, Mark J., Leo, Elisabetta
Publicado 2020

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

por Staniszewska, Anna D., Armenia, Joshua, King, Matthew, Michaloglou, Chrysiis, Reddy, Avinash, Singh, Maneesh, San Martin, Maryann, Prickett, Laura, Wilson, Zena, Proia, Theresa, Russell, Deanna, Thomas, Morgan, Delpuech, Oona, O’Connor, Mark J., Leo, Elisabetta, Angell, Helen, Valge-Archer, Viia
Publicado 2022

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer

por Teo, Zhi Ling, O’Connor, Mark J., Versaci, Stephanie, Clarke, Kylie A., Brown, Emmaline R., Percy, Luke W., Kuykhoven, Keilly, Mintoff, Christopher P., Savas, Peter, Virassamy, Balaji, Luen, Stephen J., Byrne, Ann, Sant, Sneha, Lindeman, Geoffrey J., Darcy, Phillip K., Loi, Sherene
Publicado 2023